The Monstrous Impact of Ozempic
The world can’t afford millions of prescriptions for the weight loss and diabetes medication Ozempic.
Worldwide, well over half a billion people are diabetic. More than a billion are obese. These are growing problems in every country on the planet. Diabetes and obesity impair health, longevity, and quality of life. The real ravages of obesity and diabetes are far more destructive than any fictional rampage by Godzilla.
Millions of people are taking Ozempic, a glucagon-like polypeptide 1 receptor agonist (GLP1) to combat one or both of the twin scourges of obesity and diabetes.
The glitterati boast of Ozempic’s slimming effects. The stock-market value of Novo Nordisk, maker of Ozempic, and other GLP1 drugs, surpassed the gross national product of its home country, Denmark, with sales of almost 5 billion dollars in the last year.
But a huge question has barely been asked, let alone answered: Will monster sales of Ozempic save us from the enormous impacts of obesity and diabetes? Not only would the financial and environmental costs be monumental, but Ozempic doesn’t address the root causes of obesity or diabetes. Besides, Ozempic may have a greater impact on human behavior than we have bargained for.
